Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Celanese Corporation (NYSE: CE), a global specialty materials company, today announced plans to explore the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.

The goal is to assess the utility of combining Nanoform’s nanoparticle platform technologies with Celanese’s VitalDose® EVA copolymer delivery technology for drug-eluting implants. The aims are to enable the development of next-generation drug delivery devices that support increased drug load and possess enhanced sustained release properties. Nanoform and Celanese intend to work on formulation development, leveraging each organization’s unique formulation expertise.

“We are delighted to announce the relationship with Celanese. One of Nanoform’s fundamental goals is to enable next-generation drug therapies using our nanoparticles. Given the inherent difficulty in loading a sufficient amount of drug into many medical devices, we see a tremendous opportunity in using our nanoparticles to overcome this fundamental challenge. The potential to leverage the combination of these two technologies to bring new therapies to patients is something we are very excited about,” said Edward Hæggström, CEO of Nanoform.

“Celanese has a strong history of successfully developing drug-eluting implants for women’s health, ophthalmology, and central nervous system disorders using our VitalDose® EVA copolymer delivery technology with proteins, peptides and small molecules. Exploring Nanoform’s nanoparticle technologies opens up new possibilities for enhancing formulation performance with existing products and for enabling the products of the future. We are pleased to work with Nanoform and hope that these efforts yield innovations we can bring to patients,” said Laura Brand, Celanese Vice President, Medical & Pharmaceuticals.

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications.